ArticleThe British journal of ophthalmology2007
Biological response modifier therapy for refractory childhood uveitis.
Article in The British journal of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis.Orphanet journal of rare diseases · 2020Pooled it
- Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.Drug design, development and therapy · 2018Pooled it
- Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.Rheumatology international · 2012Guideline
- Trial
- High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.American journal of ophthalmology · 2009Trial
- High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.Journal of autoimmunity · 2008Trial
- Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.Journal of clinical medicine · 2026Article
- Adalimumab to treat noninfectious pediatric chronic anterior uveitis: a case series.International ophthalmology · 2024Article
- Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review.Clinical rheumatology · 2020Review
- Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis.Pediatric rheumatology online journal · 2019Article
- Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.Annals of the rheumatic diseases · 2018Article
- Diagnosis and Management of Multiple Sclerosis in Children.Iranian journal of child neurology · 2016Review
- The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.Paediatric drugs · 2015Review
- Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.American journal of ophthalmology · 2015Article
- Review of Systemic Immunosuppression for Autoimmune Uveitis.Ophthalmology and therapy · 2014Review
- Judicious use of biologicals in juvenile idiopathic arthritis.Current rheumatology reports · 2014Review
- Adalimumab for treatment of idiopathic frosted branch angiitis: a case report.Journal of ophthalmic & vision research · 2013Article
- Response of pediatric uveitis to tumor necrosis factor-α inhibitors.The Journal of rheumatology · 2013Article
- Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Mediators of inflammation · 2013Review
- Systemic treatments for noninfectious vitreous inflammation.Mediators of inflammation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the use of biological response modifiers (BRM) in the treatment of refractory childhood uveitis.
designRetrospective non-comparative case series of pediatric patients with uveitis treated with BRM.
participants23 pediatric patients.
methodsAll children (18 years or younger) who received a BRM were assessed for visual changes, time to control inflammation, and any associated adverse side effects. Thirteen patients were treated with infliximab, five with adalimumab, and five with daclizumab. All patients had bilateral eye involvement. Diagnoses of the participants included juvenile idiopathic arthritis, keratouveitis, sarcoid panuveitis, Adamantiades-Behcets disease, and idiopathic panuveitis.
main outcome measuresInflammation and visual acuity.
resultsIn the infliximab group 16 of 26 eyes (62%), and 10 of 13 patients (77%) demonstrated an improvement in visual acuity. Twenty of 26 eyes (77%) demonstrated an improvement in the degree of inflammation. In the adalimumab group, four of 10 eyes (40%) demonstrated an improvement in visual acuity, with five of 10 eyes (50%) demonstrating an improvement in inflammation. Four of 10 eyes (40%) in the daclizumab group demonstrated an improvement in vision with eight of 10 eyes (80%) demonstrating an improvement in inflammation.
conclusionBRM appear to be safe to use in children, and represent a useful therapeutic adjunctive drug group for treating recalcitrant childhood uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.